Vanda Pharmaceuticals (VNDA) EBITDA (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of EBITDA data on file, last reported at -$50.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 22.41% year-over-year to -$50.2 million; the trailing twelve-month figure through Mar 2026 stood at -$160.4 million (down 121.34% YoY), and the FY2025 full-year result was -$151.2 million, down 271.79% from the prior year.
• EBITDA fell to -$50.2 million in Q1 2026, from -$40.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $6.6 million in Q4 2022 to a low of -$50.2 million in Q1 2026.
• A 5-year average of -$14.7 million and a median of -$9.2 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA jumped 126.13% in 2023 and sank 560.83% in 2024, its largest moves.
• Tracing VNDA's EBITDA over 5 years: stood at $6.6 million in 2022, then plunged by 207.01% to -$7.1 million in 2023, then sank by 44.9% to -$10.3 million in 2024, then sank by 292.58% to -$40.4 million in 2025, then retreated by 24.46% to -$50.2 million in 2026.
• Business Quant data shows VNDA's EBITDA at -$50.2 million in Q1 2026, -$40.4 million in Q4 2025, and -$31.3 million in Q3 2025.